Decreased AKT1/mTOR pathway mRNA expression in short-term bipolar disorder

European Neuropsychopharmacology

Volumn 25, Issue 4, 2015, Pages 468-473

  Machado Vieira, Rodrigo ^a,c   Zanetti, Marcus V ^a   Teixeira, Antonio L ^b   Uno, Miyuki ^a   Valiengo, Leandro L ^a   Soeiro de Souza, Marcio G ^a   Oba Shinjo, Sueli M ^c   de Sousa, Rafael T ^a   Zarate, Carlos A ^c   Gattaz, Wagner F ^a   Marie, Suely K N ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

AKT; Bipolar disorder; Depression; Lithium; MTOR; Treatment

Indexed keywords

AKT 1 PROTEIN; CELL PROTEIN; LITHIUM; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; NDUFA6 PROTEIN; PROTEIN BAD; PROTEIN BCL 2; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG; AKT1 PROTEIN, HUMAN; BAD PROTEIN, HUMAN; LITHIUM CHLORIDE; MTOR PROTEIN, HUMAN; PROTEIN KINASE B; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; TARGET OF RAPAMYCIN KINASE; TRANQUILIZER;

ADULT; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG BLOOD LEVEL; DSM-IV-TR; FEMALE; GENE EXPRESSION; HAMILTON DEPRESSION RATING SCALE; HUMAN; INTRACELLULAR SIGNALING; MAJOR DEPRESSION; MALE; MOLECULAR PATHOLOGY; NERVE CELL PLASTICITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; ADOLESCENT; BIPOLAR DISORDER; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; SIGNAL TRANSDUCTION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIMANIC AGENTS; BCL-ASSOCIATED DEATH PROTEIN; BIPOLAR DISORDER; FEMALE; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; HUMANS; LITHIUM CHLORIDE; MALE; MIDDLE AGED; NADH DEHYDROGENASE; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; SIGNAL TRANSDUCTION; STATISTICS, NONPARAMETRIC; TOR SERINE-THREONINE KINASES; YOUNG ADULT;

EID: 84928210553     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2015.02.002     Document Type: Article

References (27)

1. Benes F.M., et al. The expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia. Mol. Psychiatry 2006, 11:241-251.
2. Chalecka-Franaszek E., Chuang D.M. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc. Natl. Acad. Sci. USA 1999, 96:8745-8750.
3. Cunningham J.T., et al. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 2007, 450:736-740.
4. Chen G., et al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J. Neurochem. 1999, 72:879-882.
5. Grimes C.A., Jope R.S. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog. Neurobiol. 2001, 65:391-426.
6. Hashimoto K. Role of the mTOR signaling pathway in the rapid antidepressant action of ketamine. Expert Rev. Neurother. 2011, 11:33-36.
7. Jarskog L.F., et al. Cortical bcl-2 protein expression and apoptotic regulation in schizophrenia. Biol. Psychiatry 2000, 48:641-650.
8. Jope R.S., Bijur G.N. Mood stabilizers, glycogen synthase kinase-3beta and cell survival. Mol. Psychiatry 2002, 7(Suppl 1):S35-S45.
9. Kitagishi Y., et al. Roles of PI3K/AKT/GSK3/mTOR pathway in cell signaling of mental illnesses. Depress. Res. Treat. 2012, 2012:752563.
10. Karege F., et al. Genetic overlap between schizophrenia and bipolar disorder: a study with AKT1 gene variants and clinical phenotypes. Schizophr. Res. 2012, 135:8-14.
11. Kim H.W., et al. Altered expression of apoptotic factors and synaptic markers in postmortem brain from bipolar disorder patients. Neurobiol. Dis. 2010, 37:596-603.
12. Li N., et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
13. Liu R.J., et al. GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. Neuropsychopharmacology 2013, 38:2268-2277.
14. Machado-Vieira R., et al. Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: developing treatments using an integrated translational approach. World J. Biol. Psychiatry 2014, 15:84-95.
15. Machado-Vieira R., et al. The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord. 2009, 11(Suppl 2):92-109.
16. Machado-Vieira R., et al. Bcl-2 gene polymorphism rs956572AA increases inositol 1,4,5-trisphosphate receptor-mediated endoplasmic reticulum calcium release in subjects with bipolar disorder. Biol. Psychiatry 2011, 69:344-352.
17. Moutsatsou P., et al. Peripheral blood lymphocytes from patients with bipolar disorder demonstrate apoptosis and differential regulation of advanced glycation end products and S100B. Clin. Chem. Lab. Med. 2014, 52:999-1007.
18. Naydenov A.V., et al. Differences in lymphocyte electron transport gene expression levels between subjects with bipolar disorder and normal controls in response to glucose deprivation stress. Arch. Gen. Psychiatry 2007, 64:555-564.
19. Nciri R., et al. Neuroprotective effects of chronic exposure of SH-SY5Y to low lithium concentration involve glycolysis stimulation, extracellular pyruvate accumulation and resistance to oxidative stress. Int. J. Neuropsychopharmacol. 2013, 16:365-376.
20. Niciu M.J., et al. Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu. Rev. Pharmacol. Toxicol. 2014, 54:119-139.
21. Soeiro-de-Souza M.G., et al. Translating neurotrophic and cellular plasticity: from pathophysiology to improved therapeutics for bipolar disorder. Acta Psychiatr. Scand. 2012, 126:332-341.
22. Soeiro-de-Souza M.G., et al. Bcl-2 rs956572 polymorphism is associated with increased anterior cingulate cortical glutamate in euthymic bipolar I disorder. Neuropsychopharmacology 2013, 38:468-475.
23. Suo L., et al. Predictable chronic mild stress in adolescence increases resilience in adulthood. Neuropsychopharmacology 2013, 38:1387-1400.
24. Son H., et al. Lithium enhances long-term potentiation independently of hippocampal neurogenesis in the rat dentate gyrus. J. Neurochem. 2003, 85:872-881.
25. Thiselton D.L., et al. AKT1 is associated with schizophrenia across multiple symptom dimensions in the Irish study of high density schizophrenia families. Biol. Psychiatry 2008, 63:449-457.
26. Washizuka S., et al. Expression of mitochondria-related genes in lymphoblastoid cells from patients with bipolar disorder. Bipolar Disord. 2005, 7:146-152.
27. Zheng W., et al. The possible role of the Akt signaling pathway in schizophrenia. Brain Res. 2012, 1470:145-158.